These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 35988224)
1. Risk Models Based on Non-Cognitive Measures May Identify Presymptomatic Alzheimer's Disease. Yang J; Oveisgharan S; Liu X; Wilson RS; Bennett DA; Buchman AS J Alzheimers Dis; 2022; 89(4):1249-1262. PubMed ID: 35988224 [TBL] [Abstract][Full Text] [Related]
2. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients. Pichet Binette A; Palmqvist S; Bali D; Farrar G; Buckley CJ; Wolk DA; Zetterberg H; Blennow K; Janelidze S; Hansson O Alzheimers Res Ther; 2022 Mar; 14(1):46. PubMed ID: 35351181 [TBL] [Abstract][Full Text] [Related]
3. Sensitivity of Individual and Composite Test Scores from the Cogstate Brief Battery to Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease. White JP; Schembri A; Prenn-Gologranc C; Ondrus M; Katina S; Novak P; Lim YY; Edgar C; Maruff P J Alzheimers Dis; 2023; 96(4):1781-1799. PubMed ID: 38007647 [TBL] [Abstract][Full Text] [Related]
4. Predicting progression from mild cognitive impairment to Alzheimer's disease on an individual subject basis by applying the CARE index across different independent cohorts. Chen J; Chen G; Shu H; Chen G; Ward BD; Wang Z; Liu D; Antuono PG; Li SJ; Zhang Z; Aging (Albany NY); 2019 Apr; 11(8):2185-2201. PubMed ID: 31078129 [TBL] [Abstract][Full Text] [Related]
5. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593 [TBL] [Abstract][Full Text] [Related]
6. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment. Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L; Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868 [TBL] [Abstract][Full Text] [Related]
7. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia. Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799 [TBL] [Abstract][Full Text] [Related]
8. Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease. Silva D; Cardoso S; Guerreiro M; Maroco J; Mendes T; Alves L; Nogueira J; Baldeiras I; Santana I; de Mendonça A J Alzheimers Dis; 2020; 74(3):785-796. PubMed ID: 32083585 [TBL] [Abstract][Full Text] [Related]
9. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM; J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495 [TBL] [Abstract][Full Text] [Related]
10. Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer's disease in patients with mild cognitive symptoms. Arvidsson I; Strandberg O; Palmqvist S; Stomrud E; Cullen N; Janelidze S; Tideman P; Heyden A; Åström K; Hansson O; Mattsson-Carlgren N Alzheimers Res Ther; 2024 Mar; 16(1):61. PubMed ID: 38504336 [TBL] [Abstract][Full Text] [Related]
11. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. Mangialasche F; Solomon A; Kåreholt I; Hooshmand B; Cecchetti R; Fratiglioni L; Soininen H; Laatikainen T; Mecocci P; Kivipelto M Exp Gerontol; 2013 Dec; 48(12):1428-35. PubMed ID: 24113154 [TBL] [Abstract][Full Text] [Related]
12. Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study. Palmqvist S; Hertze J; Minthon L; Wattmo C; Zetterberg H; Blennow K; Londos E; Hansson O PLoS One; 2012; 7(6):e38639. PubMed ID: 22761691 [TBL] [Abstract][Full Text] [Related]
13. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241 [TBL] [Abstract][Full Text] [Related]
14. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia. Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536 [TBL] [Abstract][Full Text] [Related]
15. Predictive models of Alzheimer's disease dementia risk in older adults with mild cognitive impairment: a systematic review and critical appraisal. Wang X; Zhou S; Ye N; Li Y; Zhou P; Chen G; Hu H BMC Geriatr; 2024 Jun; 24(1):531. PubMed ID: 38898411 [TBL] [Abstract][Full Text] [Related]
16. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia]. Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ; Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080 [TBL] [Abstract][Full Text] [Related]
17. Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort. Liu P; Wu L; Peng G; Han Y; Tang R; Ge J; Zhang L; Jia L; Yue S; Zhou K; Li L; Luo B; Wang B Brain Behav Immun; 2019 Aug; 80():633-643. PubMed ID: 31063846 [TBL] [Abstract][Full Text] [Related]
18. Improved Accuracy of the Addenbrooke's Cognitive Examination-Revised in the Diagnosis of Mild Cognitive Impairment, Mild Dementia Due to Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Mokken Scale Analysis. Amaral-Carvalho V; Bento Lima-Silva T; Inácio Mariano L; Cruz de Souza L; Cerqueira Guimarães H; Santoro Bahia V; Nitrini R; Tonidandel Barbosa M; Sanches Yassuda M; Caramelli P J Alzheimers Dis; 2024; 100(s1):S45-S55. PubMed ID: 39031367 [TBL] [Abstract][Full Text] [Related]
19. Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns. Lerch O; Ferreira D; Stomrud E; van Westen D; Tideman P; Palmqvist S; Mattsson-Carlgren N; Hort J; Hansson O; Westman E Alzheimers Res Ther; 2024 Jul; 16(1):153. PubMed ID: 38970077 [TBL] [Abstract][Full Text] [Related]
20. Visuospatial memory impairment as a potential neurocognitive marker to predict tau pathology in Alzheimer's continuum. Seo EH; Lim HJ; Yoon HJ; Choi KY; Lee JJ; Park JY; Choi SH; Kim H; Kim BC; Lee KH Alzheimers Res Ther; 2021 Oct; 13(1):167. PubMed ID: 34627371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]